Highbridge Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Highbridge Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-52,173	Closed	-$793K	–	1753
2017 Q4	$793K	Buy	52,173 +6,068	+13%	+$90.1K	0.01%	671
2017 Q3	$826K	Buy	+46,105	New	+$772K	0.01%	679
2016 Q4	–	Sell	-59,854	Closed	-$996K	–	1617
2016 Q3	$996K	Buy	+59,854	New	+$806K	0.02%	567
2016 Q1	–	Sell	-17,423	Closed	-$162K	–	1839
2015 Q4	$162K	Buy	+17,423	New	+$174K	﹤0.01%	1387
2015 Q2	–	Sell	-45,112	Closed	-$420K	–	1691
2015 Q1	$420K	Buy	45,112 +10,758	+31%	+$122K	0.01%	1016
2014 Q4	$492K	Buy	+34,354	New	+$407K	0.01%	823
2013 Q4	–	Sell	-230,749	Closed	-$2.53M	–	1344
2013 Q3	$2.53M	Buy	+230,749	New	+$2.47M	0.03%	463

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Highbridge Capital Management's VNDA Position: Q1 2018 in Review

Highbridge Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2018, closing a stake of 52,173 shares — an estimated $793K sold.

Highbridge Capital Management first reported a position in VNDA in Q3 2013 and held it in 7 quarters. The position peaked at $2.53M in Q3 2013. 131 funds tracked by Wall St. Rank hold VNDA as of Q1 2018.

Highbridge Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Highbridge Capital Management sold 52,173 Vanda Pharmaceuticals shares in Q1 2018, an estimated $793K.
Highbridge Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Highbridge Capital Management's Vanda Pharmaceuticals position peaked at $2.53M in Q3 2013.
131 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2018.

Based on Highbridge Capital Management's 13F filing for Q1 2018, filed 15 May 2018.